Multiparametric Magnetic Resonance Imaging Predicts Clinical Outcomes in Patients with Chronic Liver Disease

Overview

Journal J Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2015 Oct 17

PMID 26471505

Citations 113

Authors

Michael Pavlides

Rajarshi Banerjee

Joanne Sellwood

Catherine J Kelly

Matthew D Robson

Jonathan C Booth

Jane Collier

Stefan Neubauer

Eleanor Barnes

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Multiparametric magnetic resonance (MR) imaging has been demonstrated to quantify hepatic fibrosis, iron, and steatosis. The aim of this study was to determine if MR can be used to predict negative clinical outcomes in liver disease patients.

Methods: Patients with chronic liver disease (n=112) were recruited for MR imaging and data on the development of liver related clinical events were collected by medical records review. The median follow-up was 27months. MR data were analysed blinded for the Liver Inflammation and Fibrosis score (LIF; <1, 1-1.99, 2-2.99, and ⩾3 representing normal, mild, moderate, and severe liver disease, respectively), T2∗ for liver iron content and proportion of liver fat. Baseline liver biopsy was performed in 102 patients.

Results: Liver disease aetiologies included non-alcoholic fatty liver disease (35%) and chronic viral hepatitis (30%). Histologically, fibrosis was mild in 54 (48%), moderate in 17 (15%), and severe in 31 (28%) patients. Overall mortality was 5%. Ten patients (11%) developed at least one liver related clinical event. The negative predictive value of LIF<2 was 100%. Two patients with LIF 2-2.99 and eight with LIF⩾3 had a clinical event. Patients with LIF⩾3 had a higher cumulative risk for developing clinical events, compared to those with LIF<1 (p=0.02) and LIF 1-1.99 (p=0.03). Cox regression analysis including all 3 variables (fat, iron, LIF) resulted in an enhanced LIF predictive value.

Conclusions: Non-invasive standardised multiparametric MR technology may be used to predict clinical outcomes in patients with chronic liver disease.

Citing Articles

FAP-catalyzed in situ self-assembly of magnetic resonance imaging probe for early and precise staging of liver fibrosis.

Wu Z, Zeng W, Yang W, Yi J, Liu D, Xu Y Sci Adv. 2025; 11(11):eadt6082.

PMID: 40073128 PMC: 11900868. DOI: 10.1126/sciadv.adt6082.

Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.

Brennan P, MacMillan M, Manship T, Moroni F, Glover A, Troland D Nat Med. 2025; .

PMID: 39794616 DOI: 10.1038/s41591-024-03406-8.

Practical approach to quantitative liver and pancreas MRI in children.

Kemp J, Ghosh A, Dillman J, Krishnasarma R, Manhard M, Tipirneni-Sajja A Pediatr Radiol. 2025; 55(1):36-57.

PMID: 39760887 DOI: 10.1007/s00247-024-06133-x.

Accelerated 2D radial Look-Locker T1 mapping using a deep learning-based rapid inversion recovery sampling technique.

Ahanonu E, Goerke U, Johnson K, Toner B, Martin D, Deshpande V NMR Biomed. 2024; 37(12):e5266.

PMID: 39358992 PMC: 11892465. DOI: 10.1002/nbm.5266.

MRI-serum-based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: A multisite European study.

Schaapman J, Shumbayawonda E, Castelo-Branco M, Caseiro Alves F, Costa T, Fitzpatrick E Liver Transpl. 2024; .

PMID: 39171987 PMC: 11827683. DOI: 10.1097/LVT.0000000000000450.

References

Huang Y, Yang S, Fu S, Wang T, Hsu C, Chen D . Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology. 2014; 60(3):807-14. DOI: 10.1002/hep.27212. View

Torok N, Dranoff J, Schuppan D, Friedman S . Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology. 2015; 62(2):627-34. PMC: 4515973. DOI: 10.1002/hep.27720. View

Kim K, Park M, Kim I, Kiefer B, Chung W, Kim M . Quantitative evaluation of liver cirrhosis using T1 relaxation time with 3 tesla MRI before and after oxygen inhalation. J Magn Reson Imaging. 2012; 36(2):405-10. DOI: 10.1002/jmri.23620. View

Hines C, Bley T, Lindstrom M, Reeder S . Repeatability of magnetic resonance elastography for quantification of hepatic stiffness. J Magn Reson Imaging. 2010; 31(3):725-31. PMC: 2901399. DOI: 10.1002/jmri.22066. View

Nascimbeni F, Lebray P, Fedchuk L, Oliveira C, Alvares-da-Silva M, Varault A . Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. Clin Gastroenterol Hepatol. 2014; 13(4):763-71.e1-6. DOI: 10.1016/j.cgh.2014.07.037. View

ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

Lok A, Everhart J, Chung R, Kim H, Everson G, Hoefs J . Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009; 49(6):1828-37. PMC: 2692566. DOI: 10.1002/hep.22865. View

Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T . A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013; 59(3):550-6. DOI: 10.1016/j.jhep.2013.04.027. View

Banerjee R, Pavlides M, Tunnicliffe E, Piechnik S, Sarania N, Philips R . Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2013; 60(1):69-77. PMC: 3865797. DOI: 10.1016/j.jhep.2013.09.002. View

10.

Piechnik S, Ferreira V, DallArmellina E, Cochlin L, Greiser A, Neubauer S . Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010; 12:69. PMC: 3001433. DOI: 10.1186/1532-429X-12-69. View

11.

Wong V, Chu W, Wong G, Chan R, Chim A, Ong A . Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2011; 61(3):409-15. DOI: 10.1136/gutjnl-2011-300342. View

12.

Robic M, Procopet B, Metivier S, Peron J, Selves J, Vinel J . Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011; 55(5):1017-24. DOI: 10.1016/j.jhep.2011.01.051. View

13.

Bohte A, de Niet A, Jansen L, Bipat S, Nederveen A, Verheij J . Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol. 2013; 24(3):638-48. DOI: 10.1007/s00330-013-3046-0. View

14.

Mahajan R, Gupta K . Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies. J Pharm Bioallied Sci. 2010; 2(4):307-13. PMC: 2996064. DOI: 10.4103/0975-7406.72130. View

15.

. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003; 38(4):533-40. DOI: 10.1016/s0168-8278(03)00083-7. View

16.

Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani E, Pawlotsky J . Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003; 52(2):288-92. PMC: 1774979. DOI: 10.1136/gut.52.2.288. View

17.

Ichikawa S, Motosugi U, Morisaka H, Sano K, Ichikawa T, Tatsumi A . Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis. Magn Reson Imaging. 2014; 33(1):26-30. DOI: 10.1016/j.mri.2014.10.003. View

18.

Shepard C, Finelli L, Alter M . Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558-67. DOI: 10.1016/S1473-3099(05)70216-4. View

19.

Rawlins S, Mullen C, Simon H, Kim T, Landas S, Walser M . Wedge and needle liver biopsies show discordant histopathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Gastroenterol Rep (Oxf). 2014; 1(1):51-7. PMC: 3941435. DOI: 10.1093/gastro/got006. View

20.

Wyatt J, Baker H, Prasad P, Gong Y, Millson C . Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol. 2004; 57(4):402-6. PMC: 1770262. DOI: 10.1136/jcp.2003.009357. View